The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

It's become increasingly clear that the gut microbiome can affect human health, including mental health. Which bacterial ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...